RE-BVS – Piemonte Repository

Sfoglia per AUTORE
TUCCI M
Collezione ASL Torino 4

Items : 10

Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis. in Tumori / Tumori. 2023 Apr;109(2):233-243. doi: 10.1177/03008916221077144. Epub 2022 Mar 31.

2023
ASL Asti
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Buttigliero C; Di Maio M; Scagliotti GV; Ungaro A; Parlagreco E; Audisio A; Audisio M; Angusti T; Parente A; Di Stefano RF; Urban S; Pisano C; Samuelly A; Tucci M; Turco F;

New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine? in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2022 Jun;174:103682. doi: 10.1016/j.critrevonc.2022.103682. Epub 2022 Apr 11

2022
ASL Asti
ASL Torino 4
ASL Cuneo 1
ASL Cuneo 2
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Buttigliero C; Scagliotti GV; Di Maio M; Ortega C; Di Prima L; Audisio A; Turco F; Ungaro A; Parlagreco E; Di Stefano RF; Audisio M; Tucci M;

New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond. in Cells / Cells. 2022 Jan 21;11(3):357. doi: 10.3390/cells11030357.

2022
ASL Asti
ASL Torino 4
AOU San Luigi di Orbassano

Tucci M; Di Prima L; Turco F; Di Stefano RF; Ungaro A; Audisio M; Parlagreco E; Delcuratolo MD; Audisio A; Buttigliero C;

Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside. in Cells / Cells. 2022 Feb 25;11(5):803. doi: 10.3390/cells11050803.

2022
ASL Asti
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Delcuratolo MD; Ungaro A; Buttigliero C; Di Maio M; Audisio A; Di Prima L; Turco F; Scagliotti GV; Pisano C; Tucci M;

Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective study. in Minerva urology and nephrology / Minerva Urol Nephrol. 2022 Dec;74(6):703-713. doi: 10.23736/S2724-6051.22.04701-2. Epub 2022 Feb 11.

2022
ASL Asti
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Pisano C; DI Maio M; Tucci M; Scagliotti GV; Samuelly A; DI Stefano RF; Turco F; Bungaro M; Parente A; Buttigliero C; Angusti T;

Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy. in Cancer communications (London, England) / Cancer Commun (Lond). 2022 Aug;42(8):683-688. doi: 10.1002/cac2.12340. Epub 2022 Jul 22.

2022
ASL Asti
ASL Cuneo 2
ASL Torino 4
ASL Cuneo 1
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Turco F; Ungaro A; Audisio M; Scagliotti GV; Di Maio M; Delcuratolo MD; Audisio A; Ortega C; Pisano C; Buttigliero C; Di Stefano RF; Tucci M;

Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. in Minerva urology and nephrology / Minerva Urol Nephrol. 2021 Dec;73(6):803-814. doi: 10.23736/S2724-6051.21.04186-2. Epub 2021 Mar 29.

2021
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli
ASL Torino 4
AO Ordine Mauriziano

Buttigliero C; DI Maio M; Scagliotti GV; Tarenghi F; Vignani F; Bungaro M; Samuelly A; Turco F; DI Stefano RF; Tucci M; Pisano C;

Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough? in Minerva urology and nephrology / Minerva Urol Nephrol. 2021 Dec;73(6):870-872. doi: 10.23736/S2724-6051.21.04817-5.

2021
ASL Asti
ASL Torino 4
AOU San Luigi di Orbassano

Tucci M; Turco F; Buttigliero C;

A year of pandemic COVID-19: Results from three consecutive AIOM surveys among oncology health workers in the North-West of Italy in Tumori

2021
ASL Torino 3
ASL Torino 5
ASL Torino 4
ASL VCO
ASL Alessandria
ASL Asti
AOU Città della Salute di Torino
ASL Città di Torino
AOU Alessandria
ASL Biella

Di Maio M; Buffoni L; Traverso E; Tucci M; Fanchini L; Pignataro D; Saggia C; Carnio S; Bustreo S; Buosi R; Vavalà T; Boglione A; Spadi R; Bironzo P;

Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen in Annals of Oncology

2009
ASL Torino 4
AO Ordine Mauriziano

Vignani F; Russo L; Tucci M; Motta M; Vellani G; Tampellini M; Papotti M; Dogliotti L; Berruti A;